Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Sponsored by National Cancer Institute (NCI)
About this study
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Enrolling at this location
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, Michigan
I'm interestedThis study also enrolls at 344 other locations. See all.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.